Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy.

Jindal A, Mohi MK, Kaur M, Kaur B, Singla R, Singh S.

J Midlife Health. 2015 Apr-Jun;6(2):59-65. doi: 10.4103/0976-7800.158947.

2.

The molecular, cellular and clinical consequences of targeting the estrogen receptor following estrogen deprivation therapy.

Fan P, Maximov PY, Curpan RF, Abderrahman B, Jordan VC.

Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:245-63. doi: 10.1016/j.mce.2015.06.004. Epub 2015 Jun 5. Review.

3.

The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.

Craig Jordan V, McDaniel R, Agboke F, Maximov PY.

Steroids. 2014 Nov;90:3-12. doi: 10.1016/j.steroids.2014.06.009. Epub 2014 Jun 17.

4.

The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.

Maximov PY, Lee TM, Jordan VC.

Curr Clin Pharmacol. 2013 May;8(2):135-55. Review.

5.

Profile of V. Craig Jordan.

Gupta S.

Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):18876-8. doi: 10.1073/pnas.1117698108. Epub 2011 Nov 16. No abstract available.

6.

Recruitment of representative samples for low incidence cancer populations: do registries deliver?

Clinton-McHarg T, Carey M, Sanson-Fisher R, Tracey E.

BMC Med Res Methodol. 2011 Jan 16;11(1):5. doi: 10.1186/1471-2288-11-5.

7.

Benefits and adverse effects of endocrine therapy.

Colleoni M, Giobbie-Hurder A.

Ann Oncol. 2010 Oct;21 Suppl 7:vii107-11. doi: 10.1093/annonc/mdq281. Review.

8.

Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production.

Smith DD, Tan X, Tawfik O, Milne G, Stechschulte DJ, Dileepan KN.

J Physiol Pharmacol. 2010 Jun;61(3):309-16. Erratum in: J Physiol Pharmacol. 2011 Feb;62(1):131.

9.

Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer.

Sehdev S, Martin G, Sideris L, Lam W, Brisson S.

Curr Oncol. 2009 Jul;16 Suppl 2:S14-23.

10.
11.

Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids.

Francini G, Petrioli R, Montagnani A, Cadirni A, Campagna S, Francini E, Gonnelli S.

Br J Cancer. 2006 Jul 17;95(2):153-8.

12.

Tamoxifen treatment reverses the adverse effects of chemotherapy-induced ovarian failure on serum lipids.

Vehmanen L, Saarto T, Blomqvist C, Taskinen MR, Elomaa I.

Br J Cancer. 2004 Aug 2;91(3):476-81.

14.

Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.

Decensi A, Robertson C, Rotmensz N, Severi G, Maisonneuve P, Sacchini V, Boyle P, Costa A, Veronesi U.

Br J Cancer. 1998 Sep;78(5):572-8.

15.

Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer.

Howell A, DeFriend DJ, Robertson JF, Blamey RW, Anderson L, Anderson E, Sutcliffe FA, Walton P.

Br J Cancer. 1996 Jul;74(2):300-8.

17.
18.

Supplemental Content

Support Center